Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon

TCT 2016: Hybrid sirolimus-eluting stent does not meet primary endpoint versus everolimus-eluting stent

A prospective, randomized trial failed to show non-inferiority of a hybrid sirolimus-eluting stent with biodegradable polymer versus an everolimus-eluting stent with durable polymer with regards to the primary endpoint of in-segment late lumen loss among patients who had successful chronic total occlusions recanalization.

TCT 2016: COLOR trial finds PCI of lipid-rich plaque is safe

Contrary to previous findings, placing a stent in a valve clogged with lipid-rich plaque does not pose a greater risk of adverse outcomes compared to performing the procedure on non-lipid-rich plaque. 

TCT 2016: Follow-up coronary angiography does not provide clinical benefits following PCI

A prospective, randomized trial in Japan found that follow-up coronary angiography following successful PCI had no clinical benefits and was associated with increased early revascularization rates.

Thumbnail

TCT 2016: EXCEL, NOBLE present conflicting findings on eluting stents, bypass surgery

Two new trials on eluting heart stents designed to treat unprotected left main coronary artery disease were presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2016 conference, and they have left cardiologists stumped over their conflicting findings. 

TCT 2016: PFO closure is more effective than medical management in preventing recurrent stroke

Late-breaking results from the RESPECT trial show that recommended anticoagulants or antiplatelet drugs are less effective than surgical intervention. 

Thumbnail

TCT 2016: Cerebral protection device used during TAVR does not meet primary endpoint

A randomized trial found that an investigational cerebral protection device captured embolic debris in 99 percent of patients undergoing transcatheter aortic valve replacement (TAVR) and did not change their neurocognitive function. However, the study did not meet its primary efficacy endpoint, which was the reduction in median new lesion volume in protected territories as assessed by MRI two to seven days after patients underwent TAVR.

TCT 2016: Fantom bioresorbable scaffold is safe, effective at 6 months

After six months, patients with coronary artery disease who received the investigational Fantom bioresorbable scaffold had a low risk of major adverse cardiovascular events, according to a prospective, multicenter trial. The device also had low late lumen loss.

Genes don’t stand alone: Genetic testing leads to incorrect diagnoses

Genetic testing provides physicians with more information to help make an accurate diagnosis. It is not a fool-proof way to ensure the diagnosis is never incorrect—as new research from Mayo Clinic shows.

Displaying 1249 - 1256 of 2712

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.